Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OmniaBio
Hamilton, Ontario, Canadaomniabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OmniaBio operates North America's largest cell and gene therapy CDMO facility, providing process development, GMP manufacturing, analytical development, and regulatory support for advanced therapeutics. The company leverages AI, robotics, and automation to improve efficiency and quality. Its first commercial-stage program involves manufacturing CARTISTEM for Medipost—a stem cell therapy for knee cartilage defects in osteoarthritis patients.
- Therapeutic areas
- OncologyEndocrinologyRheumatologyCardiovascularNeurology
- Modalities
- Cell therapiesGene therapiesGene-modified cellsViral vectorsStem cell-based therapies
- Industry
- Contract Manufacturing Organization
02
Partnerships
MedipostInvest Ontario
Beyond the preview
Go deeper on OmniaBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OmniaBio.